Vasoactive Peptides in Portal Pressure - Tabular View

This Tabular View shows the required WHO registration data elements as marked by ^†

Tracking Information

First Received Date ^†

September 13, 2005

Last Updated Date

July 25, 2007

Start Date ^†

Current Primary Outcome Measures ^†

Original Primary Outcome Measures ^†

Change History

Complete list of historical versions of study NCT00163982 on ClinicalTrials.gov Archive Site

Current Secondary Outcome Measures ^†

Original Secondary Outcome Measures ^†

Descriptive Information

Brief Title ^†

Vasoactive Peptides in Portal Pressure

Official Title ^†

Brief Summary

This study is looking at the detection of vasoactive peptides in portal hypertension.

Detailed Description

Study Phase

Study Type ^†

Interventional

Study Design ^†

Treatment, Randomized, Double-Blind, Placebo Control, Crossover Assignment, Safety/Efficacy Study

Condition ^†

Portal Hypertension

Intervention ^†

Drug: Norfloxacin

Study Arms / Comparison Groups

Publications *

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status ^†

Recruiting

Enrollment ^†

Completion Date

Primary Completion Date

Eligibility Criteria ^†

Inclusion Criteria: - HVPG >= 12 mmHg

Gender

Both

Ages

18 Years to 75 Years

Accepts Healthy Volunteers

Contacts ^††

Contact: William W Kemp, MBBS, FRACP

92762000 ext 3327

w.kemp@alfred.org.au

Location Countries ^†

Australia

Expanded Access Status

Administrative Information

NCT ID ^†

NCT00163982

Responsible Party

Secondary IDs ^††

Study Sponsor ^†

Bayside Health

Collaborators ^††

Investigators ^†

Principal Investigator:

William W Kemp, MBBS, FRACP

The Alfred

Information Provided By

Bayside Health

Verification Date

September 2005

^† Required WHO trial registration data element.
^†† WHO trial registration data element that is required only if it exists.